


Section: **Adult Medical**
Subject: **DECOMPENSATED CONGESTIVE HEART FAILURE / ACUTE CARDIOGENIC PULMONARY EDEMA**
Section #: **340.19**
Issue Date: **April 1, 2006**
Revision Date: **April 17, 2015**
Approved By: 

Page 1 of 3


Michael Lozano Jr., MD, FACEP HCFR Medical Director

1. **Clinical Intent:** The management of acute exacerbations of heart failure has evolved in recent years. It is important to understand that shortness of breath doesn't always fit into neat categories and there is frequently difficult to diagnose overlap between pulmonary congestion caused by systolic dysfunction, diastolic dysfunction, valvular heart disease, cor pulmonale, and dyspnea of a primary pulmonary nature in a patient who happens to also have a history cardiac disease. Our intent is to impact most favorably in those patients who are experiencing distress due to acute pulmonary congestion, and minimize the potential for harm in those whose condition mimics it. The clinical goal of this protocol is the resolution of the patient's respiratory distress.
2. This is an HCFR protocol where the treatments are listed in the preferred order of administration.
3. Basic ALS Treatment must include a 12 lead EKG and **oxygen** therapy
 - a. If available, continuous wave capnography monitoring should be used
4. Cardiovascular support is initially achieved through the use of **Nitroglycerin (NTG)**
 - a. Determine if there is a contraindication to the use of **NTG** (see QA points below and **Section 348 – Drug Reference**)
 - i. If **NTG** is contraindicated, move immediately to **CPAP** therapy
 - b. Administration of nitroglycerin depends upon the patient's systolic blood pressure (SBP)¹
 - i. For SBP >140 mmHg administer **NTG** 0.8 mg SL q5 minutes provided that the systolic BP remains >140 mmHg
 - ii. For SBP between 100 and 140 mmHg administer **NTG** 0.4 mg SL q5 minutes provided that the systolic BP remains >100 mmHg
 - iii. For SBP less than 100 mmHg administer **normal saline** 200 mL IV bolus once.
5. Ventilatory support is achieved through **CPAP therapy**^{2 3} and can be instituted at the same time as the **nitroglycerin** therapy
 - a. Indications
 - i. Moderate to severe respiratory distress (usually with tachycardia or hypertension)
 - ii. Tachypnea (RR > 24 breaths/min)
 - iii. Accessory muscle use or abdominal breathing
 - b. Contraindications
 - i. Apnea, respiratory arrest or ineffective spontaneous respirations
 - ii. Medically unstable (SBP <100 mmHg; think cardiogenic shock (**HCFR CARDIOGENIC SHOCK** protocol))
 - iii. Unable to protect airway
 - iv. Excessive secretions
 - v. Uncooperative or agitated

¹ Collins S, Storrow AB, Kirk JD, et al. Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. Ann Emerg Med 2008; 51:45–57.

² Mal, S., McLeod, S., Iansavichene, et al. (2014). Effect of out-of-hospital noninvasive positive-pressure support ventilation in adult patients with severe respiratory distress: a systematic review and meta-analysis. Annals of emergency medicine, 63(5), 600-607.

³ Goodacre, S., Stevens, J. W., Pandor, et al. (2014). Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Meta-analysis, and Individual Patient Data Meta-analysis. Academic Emergency Medicine, 21(9), 960-970.


Section: **Adult Medical**
Subject: **DECOMPENSATED CONGESTIVE HEART FAILURE / ACUTE CARDIOGENIC PULMONARY EDEMA**
Section #: **340.19**
Issue Date: **April 1, 2006**
Revision Date: **April 17, 2015**
Approved By: 

Page 2 of 3

Michael Lozano Jr., MD, FACEP HCFR Medical Director

- vi. Unable to fit the mask or to keep it on continuously
 - vii. Recent (<30 days) upper airway or upper gastrointestinal surgery
 - c. Start at 5 cm H₂O, and increase in increments of 2 cm H₂O, as tolerated by the patient
 - i. Use the lowest amount of pressure that produces an improvement in symptoms
 - ii. The target goal of therapy is a respiratory rate <25 breaths/min and oxygen saturation >90%, with hemodynamic stability; however, patient comfort or preference may be just as important an outcome measure.⁴
 - d. Use continuous wave capnography, if available, to better monitor the clinical course
 - e. If the patient's condition deteriorates to the point that they have developed a contraindication to its use, then discontinue **CPAP therapy** immediately
- 6. Maintenance nitrate therapy may be used if the patient responded well to **NTG SL**
 - a. **IV Nitroglycerin (Tridil®)** may be started if there is sufficient SBP, and you anticipate a long transport
 - i. Use of an IV pump is required for administration of **Tridil®**
 - ii. It is highly recommended that two paramedics accompany the patient in the back of the rescue when infusing **Tridil®**
 - iii. The starting dose is 10 mcg/min IV by infusion
 - iv. Increase by 10 mcg/min IV q5 minutes and titrate to symptoms and clinical response
 - v. There is no maximum dose assuming the patient's SBP can tolerate it
 - vi. If the SBP drops below 100 mmHg:
 - 1. Pause the infusion and administer normal saline 200 mL IV bolus once
 - b. **Nitroglycerin paste** can be used as an alternative if **Tridil®** is unavailable
 - i. The dose depends upon the SBP:
 - 1. For SBP > 100 and < 160 mmHg apply 1" to the chest
 - 2. SBP > 160 and < 200 mmHg apply 1.5" to the chest
 - 3. SBP > 200 mmHg apply 2" to the chest
- 7. Bronchospasm
 - a. If there is wheezing (bronchospasm) present that has not fully responded to CPAP administer **ipratropium bromide 0.5 mg (500 mcg) mixed with albuterol 2.5 mg** via nebulizer.
 - i. May be repeated two (2) times q20 minutes if there has been a response to the initial treatment
 - ii. Total dose maximum dose of 1.5 mg (1500 mcg) of **ipratropium bromide** and 7.5 mg of **albuterol**
 - b. If the patient's tidal volume is inadequate then consider administering **ipratropium bromide** and **albuterol** via BVM with in-line nebulizer or ETT after securing the airway.
 - c. Use continuous wave capnography, if available, to better monitor the clinical course
- 8. Consider intubation if no response to any therapy and deterioration is noted.
 - a. See **HCFR RAPID SEQUENCE INTUBATION (RSI)** protocol when indicated

⁴ Panacek EA, Kirk JD. Role of noninvasive ventilation in the management of acutely decompensated heart failure. Rev Cardiovasc Med. 2002; 3 Suppl 4:S35-40.

Section: **Adult Medical**
Subject: **DECOMPENSATED CONGESTIVE HEART FAILURE / ACUTE CARDIOGENIC PULMONARY EDEMA**
Section #: **340.19**
Issue Date: **April 1, 2006**
Revision Date: **April 17, 2015**
Approved By: 

Page 3 of 3

Michael Lozano Jr., MD, FACEP HCFR Medical Director

9. Hypotension with signs of shock
 - a. If the patient's SBP falls below 90 mmHg initiate **dopamine**
 - i. Start at 5 mcg/kg/min IV/IO infusion
 - ii. Increase by 5 mcg/kg/min q5 minutes titrating to effect
 - iii. Maximum infusion rate is 20 mcg/kg/min.
 - b. Go to HCFR **CARDIOGENIC SHOCK** protocol.
10. QA Points
 - a. Whereas in the past it was allowable with direct Medic-1 approval, **nitroglycerin** in all forms is now *contraindicated* in HCFR patients who have recently taken medications for erectile dysfunction. Because of their respective half-lives and duration of action, "recently" is defined for this protocol as being 24 hours for **sildenafil (Viagra®)**, and 48 hours for **vardeafil (Lavitra®)** or **tadalafil (Cialis®)**.
 - b. Carefully monitor the level of conscious, BP and respiratory status with these patients
 - c. Appropriate use of **CPAP therapy** can often stave off respiratory failure and the need for intubation.^{5 6}
 - d. Allow the patient to be in a position of comfort to maximize breathing effort
 - e. If CHF or cardiogenic shock resulting from an inferior (II,III,aVF) MI, **nitroglycerin** may cause hypotension requiring fluid bolus. Use caution, and monitor closely.
 - f. When using **Tridil®** or **nitroglycerin paste** do not continue to use **nitroglycerin SL**.
 - g. **Furosemide (Lasix®)** used to be a mainstay in the EMS treatment of CHF, but in the past decade its appropriateness in the EMS setting has been challenged.⁷ Recent research has shown that its routine use in this setting is associated with a 15% greater risk of an adverse effect if the patient doesn't have CHF. In the same study, paramedics were only able to identify true decompensated CHF 40% of the time.⁸

⁵ Rasanen J, Heikkila J, Downs J, et al. Continuous positive airway pressure by face mask in acute cardiogenic pulmonary edema. Am J Cardiol. 1985; 55:296-300.

⁶ Lin M, Chiang HT. The efficacy of early continuous positive airway pressure therapy in patients with acute cardiogenic pulmonary edema. J Formos Med Assoc. 1991; 90:736-43.

⁷ Jaronik J, Mikkelsen P, Fales W, et al. Evaluation of prehospital use of furosemide in patients with respiratory distress. Prehospital Emergency Care. 10(2):194-197, 2006.

⁸ Pan, A., Stiell, I. G., Dionne, R., Maloney, J. Prehospital use of furosemide for the treatment of heart failure. Emergency Medicine Journal, 2015; 32(1), 36-43.